# Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD

> **NCT03339973** · PHASE1,PHASE2 · TERMINATED · sponsor: **RHEACELL GmbH & Co. KG** · enrollment: 24 (actual)

## Conditions studied

- Peripheral Arterial Occlusive Disease

## Interventions

- **BIOLOGICAL:** allo-APZ2-PAOD
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03339973
- **Lead sponsor:** RHEACELL GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-05
- **Primary completion:** 2020-05-15
- **Final completion:** 2020-05-15
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Very slow recruitment of patients and the current COVID-19 pandemic situation.
- **Last updated:** 2020-06-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03339973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03339973, "Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03339973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*